Literature DB >> 117664

The effects of tetraiodothyroacetic and triiodothyroacetic acids on thyroid function in euthyroid and hyperthyroid subjects.

A G Burger, D Engler, C Sakoloff, V Staeheli.   

Abstract

The effects of tetraiodothyroacetic (Tetrac) and triiodothyroacetic acids (Triac) on thyroid function have been investigated in euthyroid and hyperthyroid subjects. 50, 100, 200, 400 or 800 micrograms of Triac were administered to 8 euthyroid volunteers three times (tds) over a 24 hour period. 3 X 800 micrograms Triac/24 h was sufficient to cause a significant reduction in serum T3. Tetrac, given as an iv bolus of 3600 microgram, produced a sustained reduction in serum T3 for up to 4 days after the injection. Intermediate doses of Tetrac (1200 micrograms) or Triac (400 micrograms tds) significantly reduced the TSH response to TRH (66% and 43% respectively). Seven hyperthyroid patients received Triac 200 micrograms tds for 2 days, and in 2, a rapid decrease in serum T3 was seen. Similar changes in serum T3 were also produced with iodide administration. The results suggest that 1) in euthyroidism, Tetrac and Triac act directly at the pituitary level to inhibit the TSH response to TRH; 2) in some cases of hyperthyroidism, Triac produces a block in T3 secretion by virtue of the iodide produced by its metabolism.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 117664     DOI: 10.1530/acta.0.0920455

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  7 in total

1.  Prescription for change: health supplement regulations and protecting the public interest.

Authors:  M C Scally; A Hodge; C Street
Journal:  J Natl Med Assoc       Date:  2001-06       Impact factor: 1.798

2.  Clinical hyperthyroidism due to non-neoplastic inappropriate thyrotrophin secretion.

Authors:  A W Chan; I A MacFarlane; C van Heyningen; P M Foy
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

3.  Dissociated thyromimetic effects of 3, 5, 3'-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels.

Authors:  P Beck-Peccoz; A Sartorio; C De Medici; G Grugni; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

4.  In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency.

Authors:  Simone Kersseboom; Sigrun Horn; W Edward Visser; Jiesi Chen; Edith C H Friesema; Catherine Vaurs-Barrière; Robin P Peeters; Heike Heuer; Theo J Visser
Journal:  Mol Endocrinol       Date:  2014-12

5.  Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3'-triiodothyroacetic acid (TRIAC).

Authors:  P Beck-Peccoz; G Piscitelli; M G Cattaneo; G Faglia
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

Review 6.  Recurrence of differentiated thyroid carcinoma during full TSH suppression: is the tumor now thyroid hormone dependent?

Authors:  Paul J Davis; Aleck Hercbergs; Mary K Luidens; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2014-10-08       Impact factor: 3.869

7.  Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.

Authors:  Stefan Groeneweg; Robin P Peeters; Carla Moran; Athanasia Stoupa; Françoise Auriol; Davide Tonduti; Alice Dica; Laura Paone; Klara Rozenkova; Jana Malikova; Adri van der Walt; Irenaeus F M de Coo; Anne McGowan; Greta Lyons; Femke K Aarsen; Diana Barca; Ingrid M van Beynum; Marieke M van der Knoop; Jurgen Jansen; Martien Manshande; Roelineke J Lunsing; Stan Nowak; Corstiaan A den Uil; M Carola Zillikens; Frank E Visser; Paul Vrijmoeth; Marie Claire Y de Wit; Nicole I Wolf; Angelique Zandstra; Gautam Ambegaonkar; Yogen Singh; Yolanda B de Rijke; Marco Medici; Enrico S Bertini; Sylvia Depoorter; Jan Lebl; Marco Cappa; Linda De Meirleir; Heiko Krude; Dana Craiu; Federica Zibordi; Isabelle Oliver Petit; Michel Polak; Krishna Chatterjee; Theo J Visser; W Edward Visser
Journal:  Lancet Diabetes Endocrinol       Date:  2019-07-31       Impact factor: 32.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.